How many clinical-trial readouts are scheduled for October 2026?

pdufa.bio currently tracks 41 clinical-trial readouts with dates in October 2026, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › October 2026

October 2026 clinical-trial readouts

trial-readout estimates for October 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← September 2026 November 2026 →

41 readouts

OGN · Oct 2026 (est.)

150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 — Plaque Psoriasis

PFE · Oct 2026 (est.)

Palbociclib — Metastatic Renal Cell Carcinoma

RGNX · Oct 2026 (est.)

Ranibizumab — AMD

SNDX · Oct 2026 (est.)

Revumenib — Refractory Acute Myeloid Leukemia

TENX · Oct 2026 (est.)

TNX-103 — Pulmonary Hypertension

XENE · Oct 2026 (est.)

Azetukalner — Focal Onset Seizures

ABOS · Oct 2026 (est.)

sabirnetug — Alzheimer Disease

AGEN · Oct 2026 (est.)

Balstilimab — Anatomic Stage IV Breast Cancer AJCC v8

ARWR · Oct 2026 (est.)

Plozasiran — Obesity

MIRM · Oct 2026 (est.)

Maralixibat — Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

CLDX · Oct 2026 (est.)

Barzolvolimab — Chronic Spontaneous Urticaria

COCP · Oct 2026 (est.)

CDI-988 — Norovirus

CORT · Oct 2026 (est.)

Relacorilant — Amyotrophic Lateral Sclerosis

CRNX · Oct 2026 (est.)

Atumelnant — Cushing Syndrome

EYPT · Oct 2026 (est.)

EYP-1901 — Wet Age Related Macular Degeneration

HUMA · Oct 2026 (est.)

Human Acellular Vessel — End Stage Renal Disease (ESRD)

IMVT · Oct 2026 (est.)

IMVT-1402 — Subacute Cutaneous Lupus Erythematosus

IOVA · Oct 2026 (est.)

Lifileucel plus Pembrolizumab — HPV-Associated Cervical Carcinoma

IRON · Oct 2026 (est.)

DISC-1459 — Inflammatory Bowel Disease (IBD)

PSTV · Oct 2026 (est.)

Rhenium Liposome Treatment — Leptomeningeal Metastasis

TECX · Oct 2026 (est.)

TX000045- Dose A — Pulmonary Hypertension

SLDB · Oct 2026 (est.)

SGT-003 — Duchenne Muscular Dystrophy

INCY · Oct 2026 (est.)

Povorcitinib — Prurigo Nodularis

BIIB · Oct 2026 (est.)

Litifilimab — Subacute Cutaneous Lupus Erythematosus

CSLLY · Oct 2026 (est.)

Recombinant Single-Chain Factor Viii — Congenital Hemophilia A

ADCT · Oct 2026 (est.)

Loncastuximab Tesirine — B-Cell Non-Hodgkin Lymphoma

SNY · Oct 2026 (est.)

Venglustat — Gaucher Disease Type 1

MRK · Oct 2026 (est.)

Pembrolizumab — Metastatic Uveal Melanoma

ILMN · Oct 2026 (est.)

18F-MFBG — Heart Failure

INBX · Oct 2026 (est.)

INBRX-106 — Solid Tumor

MBX · Oct 2026 (est.)

MBX 2109 — Obesity

VTRS · Oct 2026 (est.)

Cenerimod — Lupus Erythematosus, Systemic

JSPR · Oct 2026 (est.)

Briquilimab — Chronic Spontaneous Urticaria

MRK · Oct 2026 (est.)

IMG-7289 — Essential Thrombocythemia

RCUS · Oct 2026 (est.)

Zimberelimab — Non Small Cell Lung Cancer

RYTM · Oct 2026 (est.)

Setmelanotide — Prader-Willi Syndrome

SRPT · Oct 2026 (est.)

Eteplirsen — Muscular Dystrophy, Duchenne

SYRE · Oct 2026 (est.)

SPY001 — Rheumatoid Arthritis

ADAG · Oct 2026 (est.)

Pembrolizumab — Advanced/Metastatic Solid Tumors

ANNX · Oct 2026 (est.)

Tanruprubart — Geographic Atrophy

IMMP · Oct 2026 (est.)

eftilagimod alfa — Breast Carcinoma

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).